Tamayo Louis Edward 4

What Happened

• Louis Edward Tamayo, Chief Financial Officer of Lexeo Therapeutics (LXEO), received an award of 12,000 restricted stock units (RSUs) on 2026-06-29 (acquired at $0). On 2026-07-01 he sold 4,641 shares in an open-market transaction for a weighted average price of $4.49, generating approximately $20,838. The sale was executed to cover tax withholding obligations tied to the RSU release.

Key Details

• Transaction types: A (Award/Grant) — 12,000 RSUs on 2026-06-29; S (Sale) — 4,641 shares sold on 2026-07-01.
• Sale price: weighted average $4.49; individual trades ranged $4.33–$4.73. Total proceeds ≈ $20,838.
• Purpose of sale: tax withholding on RSU release (footnote F1).
• Beneficial holdings note: filing includes 89,665 RSUs (each RSU is a contingent right to one share) (footnote F3).
• Reporting/filing: Form filed 2026-07-01 covering transactions through 2026-06-29; no late filing indicated.
• Disclosure offer: reporting person will provide breakdown of shares sold at each separate sale price upon SEC, issuer, or shareholder request (footnote F2).

Context

• RSUs are awards that convert into company shares subject to vesting; the 12,000 RSUs were granted (not a market purchase). Sales to cover tax withholding are a common, routine action and do not necessarily indicate a change in insider sentiment. This filing shows both an award (A) and a routine sale (S) for tax purposes.